Dr. Mitchell H. Gold has a lifelong commitment to helping patients with cancer, stemming from the loss of his 26-year old mother to metastatic breast cancer when he was four years old. This loss served as the catalyst for Dr. Gold’s career in medicine and desire to transform scientific breakthroughs into effective therapies for patients.
As CEO of Dendreon Corporation, Dr. Gold and his team developed a new class of therapies called active cellular immunotherapy, designed to engage a patient’s own immune system against cancer. Dendreon ushered in an entirely new era in cancer treatment with the FDA approval of PROVENGE® (sipuleucel-T), in April 2010.
Dr. Gold was chairman and founder of Alpine Biosciences, a privately-held biotech company dedicated to developing the next generation of cancer and orphan disease treatments via a best-in-class nano-particle delivery system. Alpine Biosciences was sold to Cascadian Therapeutics (NASDAQ:CASC) in August 2014.
For his contributions to science and the treatment of cancer, Dr. Gold was named a runner up to Steve Jobs and Jeff Bezos for “Smartest CEO” by Fortune Magazine and was honored with the 2011 Oliver R. Grace Award by the Cancer Research Institute. He was voted “Entrepreneur of the Year” in the Pacific Northwest in 2011 by Ernst and Young, as well as the top influencer in medicine in 2010 by Seattle Magazine.
Dr. Gold is currently the founder and managing partner of Alpine BioVentures
What is Mitchell H. Gold's net worth?
The estimated net worth of Mitchell H. Gold is at least $6.58 million as of December 8th, 2023. Dr. Gold owns 101,320 shares of Alpine Immune Sciences stock worth more than $6,582,760 as of November 23rd. This net worth evaluation does not reflect any other assets that Dr. Gold may own. Additionally, Dr. Gold receives a salary of $778,200.00 as CEO at Alpine Immune Sciences. Learn More about Mitchell H. Gold's net worth.
How old is Mitchell H. Gold?
What is Mitchell H. Gold's salary?
How do I contact Mitchell H. Gold?
Has Mitchell H. Gold been buying or selling shares of Alpine Immune Sciences?
Mitchell H. Gold has not been actively trading shares of Alpine Immune Sciences over the course of the past ninety days. Most recently, Mitchell Gold sold 29,573 shares of the business's stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $20.04, for a transaction totalling $592,642.92. Learn More on Mitchell H. Gold's trading history.
Who are Alpine Immune Sciences' active insiders?
Are insiders buying or selling shares of Alpine Immune Sciences?
During the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 315,201 shares worth more than $6,164,078.30. The most recent insider tranaction occured on April, 25th when Director James N Topper sold 19 shares worth more than $1,226.83. Insiders at Alpine Immune Sciences own 42.3% of the company.
Learn More about insider trades at Alpine Immune Sciences. Information on this page was last updated on 4/25/2024.
